ENO1 and neoplasm: Of the top 22 differentially expressed genes mapping to the 1p36 SRO, 21 were downregulated in resistant derivatives affected by the deletion (Fig. S5C, D Tables S6, S7), including the dosage-dependent tumor suppressor candidate KIF1B [32] and ENO1, an essential gene whose downregulation generates a therapeutic vulnerability in 1p36 deleted cancers [33, 34].